REFRACTORY HODGKIN LYMPHOMA
Clinical trials for REFRACTORY HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo trial aims to reawaken immune system against stubborn lymphomas
Disease control Recruiting nowThis early-stage study is testing the safety and best dose of a two-drug combination for people with B-cell lymphomas that have come back or stopped responding to other treatments. The treatment pairs an immunotherapy drug (nivolumab) with a pill (ASTX727) that may help the immun…
Matched conditions: REFRACTORY HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New drug duo aims to tame Tough-to-Treat lymphomas
Disease control Recruiting nowThis study is testing whether combining two existing drugs—pembrolizumab and ATRA—can help control Hodgkin lymphoma or B-cell non-Hodgkin lymphoma that has returned or stopped responding to other treatments. It will enroll about 24 adults to see if the combination is safe and can…
Matched conditions: REFRACTORY HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: Rita Assi • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
Radioactive 'Warhead' targets tough hodgkin lymphoma in new transplant strategy
Disease control Recruiting nowThis study is testing a new two-part treatment for Hodgkin lymphoma that has not responded to or has returned after initial therapy. First, a radioactive antibody is given to seek out and kill cancer cells. Then, high-dose chemotherapy and a patient's own stem cells are used to t…
Matched conditions: REFRACTORY HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Mar 20, 2026 14:48 UTC
-
New cancer drug enters first human trials for patients out of options
Disease control Recruiting nowThis is a first-in-human study to test the safety and find the right dose of a new drug called HCB301. It is for adults with advanced solid tumors or Hodgkin lymphoma that have not responded to standard treatments. The main goals are to see what side effects occur and how the bod…
Matched conditions: REFRACTORY HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: FBD Biologics Limited • Aim: Disease control
Last updated Mar 09, 2026 14:26 UTC